Cargando…
Optimizing patient derived mesenchymal stem cells as virus carriers for a Phase I clinical trial in ovarian cancer
BACKGROUND: Mesenchymal stem cells (MSC) can serve as carriers to deliver oncolytic measles virus (MV) to ovarian tumors. In preparation for a clinical trial to use MSC as MV carriers, we obtained cells from ovarian cancer patients and evaluated feasibility and safety of this approach. METHODS: MSC...
Autores principales: | Mader, Emily K, Butler, Greg, Dowdy, Sean C, Mariani, Andrea, Knutson, Keith L, Federspiel, Mark J, Russell, Stephen J, Galanis, Evanthia, Dietz, Allan B, Peng, Kah-Whye |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567956/ https://www.ncbi.nlm.nih.gov/pubmed/23347343 http://dx.doi.org/10.1186/1479-5876-11-20 |
Ejemplares similares
-
Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus
por: Liu, Yu-Ping, et al.
Publicado: (2011) -
Curative one-shot systemic virotherapy in murine myeloma
por: Naik, Shruthi, et al.
Publicado: (2012) -
Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy
por: Miller, Amber, et al.
Publicado: (2014) -
Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV
por: Yarde, Danielle N., et al.
Publicado: (2013) -
Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an H.pylori immunostimulatory bacterial transgene
por: Viker, Kimberly B., et al.
Publicado: (2022)